The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia

Ann Hematol. 2024 Sep;103(9):3385-3398. doi: 10.1007/s00277-023-05595-7. Epub 2023 Dec 27.

Abstract

The E2A-PBX1 gene fusion is a common translocation in B-cell acute lymphoblastic leukaemia. Patients harbouring the E2A-PBX1 fusion gene typically exhibit an intermediate prognosis. Furthermore, minimal residual disease has unsatisfactory prognostic value in E2A-PBX1 B-cell acute lymphoblastic leukaemia. However, the mechanism of E2A-PBX1 in the occurrence and progression of B-cell acute lymphoblastic leukaemia is not well understood. Here, we mainly review the roles of E2A and PBX1 in the differentiation and development of B lymphocytes, the mechanism of E2A-PBX1 gene fusion in B-cell acute lymphoblastic leukaemia, and the potential therapeutic approaches.

Keywords: B-ALL; B-cell differentiation; E2A; E2A-PBX1; PBX1.

Publication types

  • Review

MeSH terms

  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology
  • Cell Differentiation
  • Homeodomain Proteins
  • Humans
  • Oncogene Proteins, Fusion* / genetics
  • Pre-B-Cell Leukemia Transcription Factor 1 / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / therapy
  • Prognosis

Substances

  • Oncogene Proteins, Fusion
  • E2A-Pbx1 fusion protein
  • Pre-B-Cell Leukemia Transcription Factor 1
  • Homeodomain Proteins